Solid lipid nanoparticles of guggul lipid as drug carrier for transdermal drug delivery.
Diclofenac sodium loaded solid lipid nanoparticles (SLNs) were formulated using guggul lipid as major lipid component and analyzed for physical parameters, permeation profile, and anti-inflammatory activity. The SLNs were prepared using melt-emulsion sonication/low temperature-solidification method and characterized for physical parameters, in vitro drug release, and accelerated stability studies, and formulated into gel. Respective gels were compared with a commercial emulgel (CEG) and plain carbopol gel containing drug (CG) for ex vivo and in vivo drug permeation and anti-inflammatory activity. The SLNs were stable with optimum physical parameters. GMS nanoparticle 1 (GMN-1) and stearic acid nanoparticle 1 (SAN-1) gave the highest in vitro drug release. Guggul lipid nanoparticle gel 3 (GLNG-3) showed 104.68 times higher drug content than CEG in receptor fluid. The enhancement ratio of GLNG-3 was 39.43 with respect to CG. GLNG-3 showed almost 8.12 times higher C(max) than CEG at 4 hours. The AUC value of GLNG-3 was 15.28 times higher than the AUC of CEG. GLNG-3 showed edema inhibition up to 69.47% in the first hour. Physicochemical properties of major lipid component govern the properties of SLN. SLN made up of guggul lipid showed good physical properties with acceptable stability. Furthermore, it showed a controlled drug release profile along with a promising permeation profile.
Department of Pharmaceutics, I.T.S. Paramedical (Pharmacy) College, Muradnagar, Ghaziabad, Ultra Pradesh 201206, India.
Praveen Kumar
PK
Gaur
Shikha
S
Mishra
Suresh
S
Purohit
D000279:Administration, Cutaneous; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D029744:Commiphora / Q000737:chemistry*; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D016503:Drug Delivery Systems; D004487:Edema / Q000188:drug therapy; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology / Q000627:therapeutic use; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry*; D008297:Male; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry / Q000648:ultrastructure; D010539:Permeability / Q000187:drug effects; D051381:Rats; D012869:Skin Absorption / Q000187:drug effects; D023422:Skin Irritancy Tests
D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D008055:Lipids; D007213:Indomethacin